Loading company…
Tokyo biotech developing nucleic acid drugs using aptamers and its Xenoligo technology for several medical conditions.
TAGCyx Biotechnologies, Inc. was established in 2007 and is headquartered in Tokyo, Japan. It develops high-performance nucleic acid drugs, including aptamers and its proprietary Xenoligo technology, targeting conditions such as interstitial cystitis, dry eye associated with Sjögren's syndrome, alopecia areata and gestational hypertension nephropathy. The company has completed 4 investment deals, most recently raising JPY 210 million in July 2021 from investors including Healthcare Innovation and the University of Tokyo Innovation Platform. CEO Chizuko Koseki leads the company.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in